OncoMed: BIO Investor Forum (OncoMed) - Oct 18, 2014 - "Phase 1a Summary"; "Tolerability profile distinct from vantictumab. Taste changes, muscle cramps, alopecia"; "On-target mild-to-moderate bone related adverse events. Risk mitigation implemented"; "Modulation of WNT pathway in patient samples"; "Nine patients stable disease >112 days" "
P1 data • Oncology
|